Medtronic (NYSE:MDT) today presented study results for its InPen smart insulin pen and its extended-wear infusion set.
Fridley, Minn.-based Medtronic touted real-world clinical results comparing glycemic outcomes for 1,736 individuals before and after using the InPen smart insulin pen for 90 days with a continuous glucose monitor (CGM).
Get the full story at our sister site, Drug Delivery Business News.